ADCT Straddle Strategy

ADCT (ADC Therapeutics S.A.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT (ADC Therapeutics S.A.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $442.6M, a beta of 1.84 versus the broader market, a 52-week range of 1.69-4.98, average daily share volume of 1.0M, a public-listing history dating back to 2020, approximately 263 full-time employees. These structural characteristics shape how ADCT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.84 indicates ADCT has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a straddle on ADCT?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current ADCT snapshot

As of May 15, 2026, spot at $3.27, ATM IV 22.90%, IV rank 0.91%, expected move 6.57%. The straddle on ADCT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this straddle structure on ADCT specifically: ADCT IV at 22.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a ADCT straddle, with a market-implied 1-standard-deviation move of approximately 6.57% (roughly $0.21 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ADCT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ADCT should anchor to the underlying notional of $3.27 per share and to the trader's directional view on ADCT stock.

ADCT straddle setup

The ADCT straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ADCT near $3.27, the first option leg uses a $3.27 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ADCT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ADCT shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$3.27	N/A
Buy 1	Put	$3.27	N/A

ADCT straddle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

ADCT straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on ADCT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on ADCT

Straddles on ADCT are pure-volatility plays that profit from large moves in either direction; traders typically buy ADCT straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

ADCT thesis for this straddle

The market-implied 1-standard-deviation range for ADCT extends from approximately $3.06 on the downside to $3.48 on the upside. A ADCT long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ADCT IV rank near 0.91% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ADCT at 22.90%. As a Healthcare name, ADCT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ADCT-specific events.

ADCT straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ADCT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ADCT alongside the broader basket even when ADCT-specific fundamentals are unchanged. Always rebuild the position from current ADCT chain quotes before placing a trade.

Frequently asked questions

What is a straddle on ADCT?: A straddle on ADCT is the straddle strategy applied to ADCT (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ADCT stock trading near $3.27, the strikes shown on this page are snapped to the nearest listed ADCT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ADCT straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ADCT straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 22.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ADCT straddle?: The breakeven for the ADCT straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ADCT market-implied 1-standard-deviation expected move is approximately 6.57%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on ADCT?: Straddles on ADCT are pure-volatility plays that profit from large moves in either direction; traders typically buy ADCT straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current ADCT implied volatility affect this straddle?: ADCT ATM IV is at 22.90% with IV rank near 0.91%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.